Compare VMD & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMD | SENS |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Machinery/Components |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 496.0M |
| IPO Year | 2018 | 2014 |
| Metric | VMD | SENS |
|---|---|---|
| Price | $9.10 | $9.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 413.2K | ★ 808.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $270,280,000.00 | $16,389,000.00 |
| Revenue This Year | $17.88 | $74.15 |
| Revenue Next Year | $14.98 | $58.60 |
| P/E Ratio | $69.15 | ★ N/A |
| Revenue Growth | ★ 20.52 | 19.85 |
| 52 Week Low | $6.05 | $0.41 |
| 52 Week High | $12.61 | $10.15 |
| Indicator | VMD | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 69.40 |
| Support Level | $8.49 | $5.13 |
| Resistance Level | $10.05 | $9.99 |
| Average True Range (ATR) | 0.28 | 0.56 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 54.55 | 79.25 |
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.